| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
In current study, we tried to identify pharmacokinetic regulatory factors of the integrase inhibitor dolutegravir with the aim of accumulating basic information for Therapeutic Drug Monitoring (TDM) of anti-HIV drugs. As a result, it became clear that dolutegravir will serve as a substrate for BCRP, an efflux transporter. It was suggested that BCRP is involved as one of pharmacokinetic regulators of dolutegravir, and obtained a useful finding for the development to clinical studies using the human blood sample in the future.
|
